Sugar Beet Pectin Supplementation Did Not Alter Profiles of Fecal Microbiota and Exhaled Breath in Healthy Young Adults and Healthy Elderly
An, Ran ; Wilms, Ellen ; Smolinska, Agnieszka ; Hermes, Gerben D.A. ; Masclee, Ad A.M. ; Vos, Paul de; Schols, Henk A. ; Schooten, Frederik J. van; Smidt, Hauke ; Jonkers, Daisy M.A.E. ; Zoetendal, Erwin G. ; Troost, Freddy J. - \ 2019
Nutrients 11 (2019)9. - ISSN 2072-6643
aging - dietary fiber - elderly - exhaled air - microbiota - pectin - young adults
Aging is accompanied with increased frailty and comorbidities, which is potentially associated with microbiome perturbations. Dietary fibers could contribute to healthy aging by beneficially impacting gut microbiota and metabolite profiles. We aimed to compare young adults with elderly and investigate the effect of pectin supplementation on fecal microbiota composition, short chain fatty acids (SCFAs), and exhaled volatile organic compounds (VOCs) while using a randomized, double-blind, placebo-controlled parallel design. Fifty-two young adults and 48 elderly consumed 15 g/day sugar beet pectin or maltodextrin for four weeks. Fecal and exhaled breath samples were collected before and after the intervention period. Fecal samples were used for microbiota profiling by 16S rRNA gene amplicon sequencing, and for analysis of SCFAs by gas chromatography (GC). Breath was used for VOC analysis by GC-tof-MS. Young adults and elderly showed similar fecal SCFA and exhaled VOC profiles. Additionally, fecal microbiota profiles were similar, with five genera significantly different in relative abundance. Pectin supplementation did not significantly alter fecal microbiota, SCFA or exhaled VOC profiles in elderly or young adults. In conclusion, aside from some minor differences in microbial composition, healthy elderly and young adults showed comparable fecal microbiota composition and activity, which were not altered by pectin supplementation.
General Framing of Low-, Mid-, and High-Level Data Fusion With Examples in the Life Sciences
Smolinska, Agnieszka ; Engel, Jasper ; Szymanska, Ewa ; Buydens, Lutgarde ; Blanchet, Lionel - \ 2019
In: Data Fusion Methodology and Applications Elsevier Ltd, Academic Press (Data Handling in Science and Technology ) - ISBN 9780444639844 - p. 51 - 79.
Analytical technique - Data fusion - Gas chromatography–mass spectrometry - Kernel-based data fusion - Liquid chromatography - Microbiome data
The constant development of analytical techniques leads to an increase in the amount of information available to describe phenomena in life science. In parallel, the inherent complexity of life science makes it almost impossible to obtain a comprehensive description using only one technical modality. Therefore, it became very popular to combine several biological or technical platforms/modalities to obtain a better understanding of the underlying problems. Merging different types of measurements/platforms into a single analysis is, however, a complex topic. Combining various platforms into single analysis is defined as data fusion. We describe here different types of data fusion strategies: the well-established low-, mid-, and high-level data fusion and the more recently introduced sustainable mid-level data fusion and kernel-based data fusion. For each type, we provide a detailed description. To illustrate these various data fusion approaches, we rely on four real data sets, namely, exhaled breath data of patients with Crohn disease (CD) obtained by gas chromatography–mass spectrometry (GC-MS), 454 pyrosequencing microbiome data of patients with CD, and metabolic profiling of beer brands by GC-MS and positive and negative ion modes of liquid chromatography.
A novel biomarker panel for irritable bowel syndrome and the application in the general population
Mujagic, Zlatan ; Tigchelaar, Ettje F. ; Zhernakova, Alexandra ; Ludwig, Thomas ; Ramiro-Garcia, Javier ; Baranska, Agnieszka ; Swertz, Morris A. ; Masclee, A.A.M. ; Wijmenga, Cisca ; Schooten, Frederik J. Van; Smolinska, Agnieszka ; Jonkers, Daisy M.A.E. - \ 2016
Scientific Reports 6 (2016). - ISSN 2045-2322
Biological markers that measure gut health and diagnose functional gastro-intestinal (GI) disorders, such as irritable bowel syndrome (IBS), are lacking. The objective was to identify and validate a biomarker panel associated with the pathophysiology of IBS that discriminates IBS from healthy controls (HC), and correlates with GI symptom severity. In a case-control design, various plasma and fecal markers were measured in a cohort of 196 clinical IBS patients and 160 HC without GI symptoms. A combination of biomarkers, which best discriminates between IBS and HC was identified and validated in an independent internal validation set and by permutation testing. The correlation between the biomarker panel and GI symptom severity was tested in IBS patients and in a general population cohort of 958 subjects. A set of 8 biomarker panel was identified to discriminate IBS from HC with high sensitivity (88.1%) and specificity (86.5%). The results for the IBS subtypes were comparable. Moreover, a moderate correlation was found between the biomarker panel and GI symptom scores in the IBS (r = 0.59, p <0.001) and the general population cohorts (r = 0.51, p = 0.003). A novel multi-domain biomarker panel has been identified and validated, which correlated moderately to GI symptom severity in IBS and general population subjects.